The Egyptian Cabinet has celebrated Egyptian scientist Dr. Magid Abou-Gharbia for winning the 2026 John Scott Award in the United States, recognizing his significant contributions to drug discovery and development, particularly treatments for cancer, depression and chronic pain.
In a statement posted on its Facebook page, the Cabinet said Abou-Gharbia holds more than 145 US patents and has helped develop nearly a dozen new drugs marketed to treat various conditions, including cancer, infectious diseases, neurological disorders, women's health conditions, bone diseases and chronic pain. He has also led multidisciplinary research teams at international scientific and pharmaceutical institutions.
The Cabinet said the John Scott Award is one of the oldest scientific honors in the United States, recognizing discoveries and innovations that benefit humanity. Abou-Gharbia was among three scientists selected for the 2026 award and received the honor at a ceremony on October 27, along with a $10,000 cash prize, in recognition of his decades of pharmaceutical research.
In a statement published on November 3, 2026, Temple University said Abou-Gharbia, Laura H. Carnell Professor and founding director of the Moulder Center for Drug Discovery Research at its School of Pharmacy, received the award for his pioneering innovations in drug discovery and development.
The university said his research has contributed to the development of nearly a dozen new medicines for a range of conditions, including cancer, infectious diseases, neurological disorders, women's health conditions, bone diseases and chronic pain.
According to the university, Abou-Gharbia was preparing to travel to Egypt to deliver a lecture when he received an unexpected email from the chair of the award's selection committee informing him that he had won. He expressed surprise, happiness and pride at the recognition.
Abou-Gharbia said he had been passionate about chemistry since childhood and viewed the award as recognition not only of his own achievements but also of the talented research teams and collaborators he had worked with over the years.
The university said Abou-Gharbia is the fifth Temple faculty member to receive the award, following Michael Klein in 2020, Masatoshi Nei in 2017, John Perdew in 2015 and Franklin Davis in 2006.
Abou-Gharbia began his career as a research scientist at Wyeth Pharmaceuticals, which was later acquired by Pfizer. He rose through the ranks to become senior vice president of drug discovery, leading research teams comprising more than 500 scientists.
Among the notable drugs he helped develop are Effexor and Pristiq, both used to treat depression; Dezocine, a painkiller; and Torisel, a treatment for kidney cancer.
Research teams under his leadership also helped develop Mylotarg, a drug introduced in 2000 that targets cancer cells while limiting the exposure of other cells to toxic substances. The treatment remains in use in chemotherapy.
The university said Abou-Gharbia returned to academia in 2008 and played a leading role in establishing the Moulder Center for Drug Discovery Research, serving as its founding director until 2020. The center was established to bring together education, scientific research and the pharmaceutical industry, helping translate laboratory discoveries into treatments for patients.
During his tenure, the center secured more than $30 million in research grants and external funding. Its research resulted in 15 US patents and the establishment of four spin-off companies.
Abou-Gharbia also served as associate dean for research at Temple University's School of Pharmacy from 2008 to 2019. He received the university's Outstanding Service Award in 2022 and was inducted into the American Chemical Society Medicinal Chemistry Hall of Fame and the New Jersey Inventors Hall of Fame.
After more than 55 years in medicinal chemistry, Abou-Gharbia continues to research and design drugs targeting alcohol and opioid addiction. He has also expressed enthusiasm for working with younger generations of researchers and students, whom he regards as the future leaders of the field.
In a report published on November 5, 2026, the American Chemical Society's Chemical & Engineering News magazine said the Board of Directors of City Trusts of Philadelphia honored the three award recipients for their contributions to the comfort, welfare and happiness of humanity.
The other recipients were Nina Jablonski of Pennsylvania State University, recognized for research that transformed the understanding of race, and Daniel Skovronsky of Eli Lilly and Company, who pioneered a first-of-its-kind diagnostic tool for Alzheimer's disease.
The magazine said the three scientists join a distinguished list of previous recipients, including Marie Curie, Thomas Edison, Irving Langmuir, who served as president of the American Chemical Society in 1929, and Glenn T. Seaborg, who led the society in 1976.